CCL22 and adenocarcinoma: Tissue microarray by immunohistochemistry was performed to test the number of CCL22+ and FOXP3+ cells in a retrospective cohort of 230 cervical cancer cases, including 187 cases of squamous carcinoma and 43 cases of adenocarcinoma.